Navigation Links
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Date:7/1/2008

riteria) was achieved with the outpatient administration of Dacogen, confirming previously reported response rates in the outpatient setting. The safety profile of this dosing regimen was consistent with what has been previously reported.

Eisai is committed to a clinical development program to optimize the utility of Dacogen for all patients with MDS. Recent studies of hypomethylating agents have suggested that treatment of patients should continue for as long as they receive clinical benefit or until their disease progresses. To advance the understanding of optimal treatment for MDS and related conditions, there are currently more than 30 ongoing trials with Dacogen either as a single agent or in combination with other therapies, including a Phase III survival study in older patients with acute myelogenous leukemia (AML).

Study Design

EORTC-06011: This Phase III open-label, randomized, multi-center, controlled trial evaluated overall survival of patients receiving Dacogen plus BSC versus BSC only. The study involved 233 elderly patients, greater than or equal to 60 years of age, with predominantly high-risk or Intermediate-2 type MDS.

Patients included in the trial had primary or secondary MDS with or without previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor-risk cytogenetics in order to be eligible for randomization.

DACO-020: This is a multi-center, open-label, single arm Phase II study of Dacogen in 99 patients with de novo or secondary MDS. Dacogen was administered daily for five days repeated every four weeks. Patients were greater than or equal to 18 years of age with MDS (de novo or secondary) of any FAB subtype and with an International Prognostic Scoring System score of greater than or equal to 0.5. In order to
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
4. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
8. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
9. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
10. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
11. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany , ... for filing the New Drug Application (NDA) for Cladribine Tablets as a ... , , ... Review designation by the FDA, which means the review period for the ...
... , SHANGHAI , July ... WX ) today announced that RiskMetrics Group,s ISS Proxy Advisory ... has recommended that WuXi shareholders vote FOR Charles River,s proposed,acquisition ... Proxy,Governance, previously recommended that WuXi shareholders vote FOR the,transaction. , ...
Cached Medicine Technology:EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 2EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 3EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 4EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS 5ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Top10BestSEOHosting.com ... evaluating many web host suppliers carefully, Top10BestSEOHosting.com is ... are the best web hosting suppliers in 2014. ... old clients with a top-of-the-line shared hosting plan. ... an easy-to-use platform that is affordable, accessible and ...
(Date:9/1/2014)... 01, 2014 Pastor Thompson is an ordained ... Eagle Village. He is a licensed minister through the Church ... past twenty years in New Mexico, Colorado and North Dakota. ... marriage this year. He also has two beautiful daughters, ... in Pastoral Ministry from Nazarene Bible College, in Colorado Springs ...
Breaking Medicine News(10 mins):Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... cosmetics shows it may have prevented, treated eye infections ... eye makeup worn thousands of years ago by Queen ... used to enhance beauty alone: New research suggests that ... eye disease. , Some ancient Egyptians thought their ...
... ... its’ addition of three exceptional leaders to their management team. Anne Reynolds and ... aboard as the Client Accounting Manager. , ... Columbus, OH (PRWEB) January 22, 2010 -- ADVOCATE, the premier ...
... ... identified brain networks damaged in Parkinson’s disease have new evidence that these systems become ... appear to respond in a last ditch attempt to rescue the brain. , ... Manhasset, NY (Vocus) January ...
... Jan. 22 Healthcare Trust of America, Inc. ... execution of a purchase and sale agreement to acquire an ... Georgia for approximately $19,550,000 . The closing of ... The medical office portfolio is 94% leased and is on ...
... Pa. , Jan. 22 ReSearch Pharmaceutical Services, Inc. ... and Steven Bell , Chief Financial Officer, will present at ... 25–27, 2010 in New York City .   , The ... 11:45 am, EST .  Mr. Perlman will also participate in ...
... find , FRIDAY, Jan. 22 (HealthDay News) -- Environment ... children,s reading skills, a new study finds. , "We ... learning, but children who come into school with poor ... author Stephen Petrill, a professor of human development and ...
Cached Medicine News:Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3Health News:ReSearch Pharmaceutical Services, Inc. to Present at Jefferies 2010 Global Healthcare Conference 2Health News:Environment Crucial to Boosting Child's Reading Skills 2
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
Medicine Products: